Back to discover
Disease

HIV Seropositivity

Late-stage therapeutic developmentEmerging research
MeSHHIV Seropositivity
1
Publications
14
Clinical trials
2015
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Research2015-07-20The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials with recent milestones.
Clinical Milestones2View
Recently completed 2
Activity timeline2

Clinical trials

9 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
14
All trials
3
Active
3
Late-stage
6
Completed
Late-stage studies

A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" Trial

Phase 4 · Active, not recruiting · The Aurum Institute NPC

Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component

Phase 4 · Completed · Helsinki University Central Hospital

Phase 3b, Single Arm, Simplification Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen. (RALAM-II Study)

Phase 3 · Terminated · Judit Pich
Recently completed

Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients

Phase 2 · Completed · Centre Hospitalier Régional d'Orléans

Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component

Phase 4 · Completed · Helsinki University Central Hospital

Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)

Phase 2 · Completed · Universidad de Antioquia

Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression

Phase 2 · Completed · The Ojai Foundation

A Pilot Study (Phase I/II) Testing the Immunologic Activity and Safety of AGS-004, an Autologous HIV Immunotherapeutic, in HIV-Infected Adults on HAART

Phase 1/2 · Completed · McGill University Health Centre/Research Institute of the McGill University Health Centre

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval.

Phase 2 · Completed · AIM ImmunoTech Inc.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

The New England journal of medicine · 2015 · 2,097 cites
Recent publications

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

The New England journal of medicine · 2015 · 2,097 cites
Leading journals1
  • The New England journal of medicine1
Leading researchers8
  • Avihingsanon A1
  • Babiker AG1
  • Collins S1
  • Cooper DA1
  • Emery S1
  • Fätkenheuer G1
  • Gordin F1
  • Grund B1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).

Identifiers
MeSHHIV Seropositivity
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.